TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06217822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-PSMA-Trillium (BAY3563254)
Description: Intravenous slow injection on Day 1 of a 6 week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-PSMA-Trillium (BAY3563254)
Description: Intravenous slow injection on Day 1 of a 6 week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-PSMA-Trillium (BAY3563254)
Description: Intravenous slow injection on Day 1 of a 6 week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-PSMA-Trillium (BAY3563254)
Description: Intravenous slow injection on Day 1 of a 6 week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-PSMA-Trillium (BAY3563254)
Description: Intravenous slow injection on Day 1 of a 6 week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-PSMA-Trillium (BAY3563254)
Description: Intravenous slow injection on Day 1 of a 6 week treatment cycle.
Study: NCT05090566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab + Nirogacestat
Description: BCMA-CD3 bispecific antibody + gamma secretase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab + lenalidomide + dexamethasone
Description: BCMA-CD3 bispecific antibody + immunomodulatory
Study: NCT05589194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Practices Based on Kolcaba's Comfort Theory
Description: Nursing interventions planned to be carried out within the scope of the research will be based on Comfort Theory. Nursing interventions will be planned according to the needs in the physical comfort (diet practice, providing effective and correct pelvic floor muscle contraction, repetitive and regular yoga practice training), psychospiritual comfort (appreciation and encouragement, self-confidence, expressing the feeling of embarrassment, expressing fear, confidence, repetitive and regular practice of yoga practice, meditation), sociocultural comfort (to be informed, to develop effective interpersonal communication, to interact with other women with SUI) and environmental comfort (Informing about making the necessary arrangements to prevent possible situations such as sleep disruption and falling, bad smell, etc. and performing nursing practices by respecting privacy). The yoga practice will carry out with the participation of 60-minute group yoga classes twice a week for 6 weeks.
Study: NCT05967364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wingman-Connect
Description: Training occurs in three 2-hr blocks over several days in class groups. Targeted Skills focus on protective factors (Four Cores) supportive of mental health, theoretically linked to reduced suicide risk, and essential to an Airmen's job success: (1) Healthy relationships and accountability spanning USAF and family/intimate relationships (Kinship); (2) Meaning and value in work and life (Purpose), (3) Informal and formal help-seeking (Guidance); and (4) Activities that give strength and balance emotions (Balance). Activities progress from individual to group skill-building activities. Kinship modules at operational base (FTAC) expand focus on growing and sustaining relationships with intimate partners, friends, and family; and Guidance more on senior mentors at work. To extend training impact, facilitators implement activities once per quarter that bring concepts into base activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: Stress management training (also done in class groups) reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
Study: NCT05334784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella ECP
Description: Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
Study: NCT06008587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIRVO3 TM
Description: A device that provides high flows of heated and humidified respiratory gases to patient who breath spontaneously. Patients will be treated with the device up to 15 days or until the occurrence of respiratory acidosis defined by pH\<7.35, whichever come first.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard therapy depends on the acute respiratory failure etiology. Treatments will be administered at the investigator's discretion in accordance with the standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy depends on the acute respiratory failure etiology. Treatments will be administered at the investigator's discretion in accordance with the standard of care.
Study: NCT04629950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: Active Agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT06181760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenretinide
Description: Ascending single doses of oral fenretinide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenretinide
Description: Ascending single doses of oral fenretinide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenretinide
Description: Ascending single doses of oral fenretinide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of matching placebo capsules
Study: NCT05726981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration biopsy (FNAB)
Description: Thyroid FNAB is a minimally invasive procedure performed routinely by an experienced sonographer.~It is a safe and brief procedure, performed with a 27G or 25G (very fine) needle (3 needles, i.e. 1 needle per pass)
Study: NCT05456373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearEdge device
Description: ClearEdge tissue imaging device uses a new technology to detect tissue abnormalities at the surgical margins of a surgically excised breast tissue specimen. Adding the use of the imaging device has the potential to assist the surgeon in identifying DCIS or invasive cancer involved margins of the excised specimen.
Study: NCT06591026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Description: One digital helpline session that includes a structured cognitive coping skills brief intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Description: One digital helpline session that includes a structured cognitive coping skills brief intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Text Messaging (ATM)
Description: Automated text messages are sent daily for 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Text Messaging (ATM)
Description: Automated text messages are sent daily for 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Text Messaging (ATM)
Description: Automated text messages are sent daily for 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Text Messaging (ATM)
Description: Automated text messages are sent daily for 4 weeks.
Study: NCT04805736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: Image-guided microwave ablation 7-10 days prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200 mg was given a few days after microwave ablation
Study: NCT06603090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message influenza vaccine reminders
Description: Text message influenza vaccine reminders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message COVID-19 vaccine reminders
Description: Text message COVID-19 vaccine reminders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message influenza and COVID-19 vaccine reminders
Description: Text message influenza and COVID-19 vaccine reminders
Study: NCT06618014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab was given 240 mg intravenously on day 1 of each 21-day cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel was administered at a dose of 75 mg/m2 on day 1 of each 21-day cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 4 on day 1 of each 21-day cycle for 6 cycles.
Study: NCT05578781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music Therapy is a music session with a live therapist and has been shown to reduce pain and anxiety. If effective the music medicine in this RCT will be used help design a full R01 study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Medicine
Description: Music Medicine is an audio recorded music therapy session that will be played for the participant. This will be the same music session that will be played live in the music therapy session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: Control group will listen to an audio recording of text being spoken by the board certified music therapist
Study: NCT06680375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT05578781

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Control group will listen to an audio recording of text being spoken by the board certified music therapist
Study: NCT06155838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Adolescent Skills for Emotions (EASE)
Description: Weekly Schedule for Teen's and their parents Sessions:~Over the course of 7 sessions, with one session per week lasting 90 minutes, the following core components will be covered:~Week 1: Exploring My Feelings~Week 2: Learning to Calm~Week 3 \& 4: Learning CBT- Restructuring My Thinking, Changing Feelings and My Actions \& Managing My Emotions and Issues~Week 5 \& 6: Fostering Independent Problem-Solving Skills and Seeking Help~Week 7: Relapse Prevention~2.0 For parents/ guardians~Week 3 Psychoeducation (to develop skills to be able to identify, listen, better respond and provide comfort to teens when they are overwhelmed by anxiety and depression).~Week 4 Positive parenting strategies~Week 5 Parents/ guardians Self-care
Study: NCT06680375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Phase 2 selected Investigational Flu Seasonal/SARS-CoV-2 mRNA
Description: An Investigational Flu Seasonal/SARS-CoV-2 mRNA with a SARS-CoV-2 mRNA dose level resulting from study Phase 1 will be administered.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Phase 2 selected Investigational Flu Seasonal/SARS-CoV-2 mRNA
Description: An Investigational Flu Seasonal/SARS-CoV-2 mRNA with a SARS-CoV-2 mRNA dose level resulting from study Phase 1 will be administered.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2 selected SARS-CoV-2 mRNA
Description: A selected SARS-CoV-2 mRNA dose level resulting from study Phase 1 will be administered.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2 selected SARS-CoV-2 mRNA
Description: A selected SARS-CoV-2 mRNA dose level resulting from study Phase 1 will be administered.
Study: NCT05370391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Description: The CBIT (or CBIT-JR) intervention consists of a minimum of 6 sessions of 50-minutes each week in an individual or group setting.
Study: NCT06683365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sural Nerve Graft to the Substantia Nigra
Description: Participants assigned to this arm will have the sural nerve biopsied from one of their ankles. This cellular tissue will be deposited bilaterally into the substantia nigra area of their brain by a specialized cannula via bilateral scalp incisions and skull burr holes.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham surgery
Description: Participants assigned to this arm will have the sural nerve from one of their ankles biopsied in the same fashion as the experimental arm. Bilateral incisions will be made on the participants scalp but no burr holes into the skull and no cannula passes into the brain will occur.
Study: NCT06683378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reparative Autologous peripheral nerve tissue
Description: At the time participants are receiving the standard of care deep brain stimulation (DBS) surgery, a standard incision on the lateral aspect near the ankle is made, the sural nerve is identified, an about 3 cm biopsy of the sural nerve is obtained and the incision is closed.~From the biopsied section, the epineurium is removed, fascicles are cut, and (\~5 pieces per side; \~ 5mm length x 1.5 mm diameter: approximately 10 cubic millimeters) implanted bilaterally into the nucleus basalis of Meynert (NBM) or substantia nigra (SN).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reparative Autologous peripheral nerve tissue
Description: At the time participants are receiving the standard of care deep brain stimulation (DBS) surgery, a standard incision on the lateral aspect near the ankle is made, the sural nerve is identified, an about 3 cm biopsy of the sural nerve is obtained and the incision is closed.~From the biopsied section, the epineurium is removed, fascicles are cut, and (\~5 pieces per side; \~ 5mm length x 1.5 mm diameter: approximately 10 cubic millimeters) implanted bilaterally into the nucleus basalis of Meynert (NBM) or substantia nigra (SN).
Study: NCT06689475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoacoustic approach
Description: The psychoacoustic approach group will listen to normal heart sounds (S1, S2), abnormal heart sounds (S3, S4) and murmur sounds from the audio file uploaded to their mobile phones in the laboratory environment through headphones for 500 repetitions each.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation
Description: The simulation group will practice auscultation of heart sounds in a one-to-one and repetitive manner, working with a high reality simulator. Trainers will act as facilitators during the cardiac auscultation practice of the students in the intervention groups.
Study: NCT06625567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animated video
Description: Patients will watch an educational video describing the procedure before hysteroscopy without anesthesia
Study: NCT05832437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BREATHE-Peds Intervention
Description: BREATHE-Peds utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
Study: NCT06646276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986489 (BMS-986012+Nivolumab)
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Specified dose on specified days
Study: NCT05216432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).
Study: NCT05832437

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
Study: NCT06633055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JH013 injection
Description: JH013 injection is a BAFF-R inhibitor monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JH013 injection
Description: JH013 injection is a BAFF-R inhibitor monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JH013 injection
Description: JH013 injection is a BAFF-R inhibitor monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JH013 injection
Description: JH013 injection is a BAFF-R inhibitor monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: JH013 injections placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: JH013 injections placebo
Study: NCT05216432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: 125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib 400mg
Description: 400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib 600mg
Description: 600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060 100mg
Description: is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060 300 mg
Description: is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
Study: NCT06633055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: JH013 injections placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: JH013 injections placebo
Study: NCT06686615

Intervention type: DRUG
Intervention: Bempedoic acid
Description: No drug was administered in this observational study.

Intervention type: DRUG
Intervention: Ezetimibe
Description: No drug was administered in this observational study.

Intervention type: DRUG
Intervention: Rosuvastatin
Description: No drug was administered in this observational study.

Intervention type: DRUG
Intervention: Atorvastatin
Description: No drug was administered in this observational study.